| Literature DB >> 27563394 |
Clemens Scheufler1, Henrik Möbitz1, Christoph Gaul1, Christian Ragot1, Céline Be1, César Fernández1, Kim S Beyer1, Ralph Tiedt1, Frédéric Stauffer1.
Abstract
Mixed lineage leukemia (MLL) gene rearrangement induces leukemic transformation by ectopic recruitment of disruptor of telomeric silencing 1-like protein (DOT1L), a lysine histone methyltransferase, leading to local hypermethylation of H3K79 and misexpression of genes (including HoxA), which drive the leukemic phenotype. A weak fragment-based screening hit identified by SPR was cocrystallized with DOT1L and optimized using structure-based ligand optimization to yield compound 8 (IC50 = 14 nM). This series of inhibitors is structurally not related to cofactor SAM and is not interacting within the SAM binding pocket but induces a pocket adjacent to the SAM binding site.Entities:
Keywords: Dot1L; fragment-based screen; inhibitor; lysine histone methyltransferase; structure-based design
Year: 2016 PMID: 27563394 PMCID: PMC4983739 DOI: 10.1021/acsmedchemlett.6b00168
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345